Treatment-refractory idiopathic hypereosinophilic syndrome: Pitfalls and progress with use of novel drugs

American Journal of Hematology

Volumn 87, Issue 7, 2012, Pages 703-706

  Bleeker, Jonathan S ^a   Syed, Faisal F ^a   Cooper, Leslie T ^a   Weiler, Catherine R ^a   Tefferi, Ayalew ^a   Pardanani, Animesh ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AMOXICILLIN; ATOVAQUONE; COTRIMOXAZOLE; DEXAMETHASONE; HEMOGLOBIN; HEPARIN; MEPOLIZUMAB; METHYLPREDNISOLONE; PEGINTERFERON ALPHA2A; PENTAMIDINE; PREDNISONE; VALACICLOVIR;

ADULT; ANTICOAGULANT THERAPY; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; BLOOD SAMPLING; BONE MARROW BIOPSY; BRAIN INFARCTION; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; DEPRESSION; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; EOSINOPHIL COUNT; EOSINOPHILIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; HYPERTRANSAMINASEMIA; HYPOTHYROIDISM; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALAISE; MONOCYTE; MYALGIA; NEUTROPHIL COUNT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; SORE THROAT; STEROID THERAPY; STROKE; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; DRUG MONITORING; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; LYMPHOPENIA; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84862550125     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23120     Document Type: Article

References (25)

1. Tefferi A, Gotlib J, Pardanani A. Hypereosinophilic syndrome and clonal eosinophilia: Point-of-care diagnostic algorithm and treatment update. Mayo Clin Proc 2010; 85: 158-164.
2. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: Secondary, clonal, and idiopathic. Br J Haematol 2006; 133: 468-492.
3. Swerdlow SH, Campo C, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th ed. IARC: Lyon, 2008.
4. Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: Analysis of fourteen cases with review of the literature. Medicine 1975; 54: 1-27.
5. Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126: 45-49.
6. Ogbogu PU, Bochner BU, Butterfield JH, et al. Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124: 1319-1325.e3.
7. Weller P, Bubley G. The idiopathic hypereosinophilic syndrome. Blood 1994; 83: 2759-2779.
8. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol 2000; 86: 110-113.
9. Debl K, Djavidani B, Buchner S, et al. Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson 2008; 10: 21.
10. Ogbogu PU, Rosing DR, Horne MKIII. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27: 457-475.
11. Cohen J, Davies J, Goodwin JF, et al. Arrhythmias in patients with hypereosinophilia: A comparison of patients with and without Löffler's endomyocardial disease. Postgrad Med J 1980; 56: 828-832.
12. Elsner J, Hochstetter R, Spiekermann K, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996; 88: 4684-4693.
13. Verstovsek S, Tefferi A, Kantarjian H, et al. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res 2009; 15: 368-373.
14. Ghobrial IM, Otteman LA, White WL. An EBV-positive lymphoproliferative disorder after therapy with alemtuzumab. N Engl J Med 2003; 349: 2570-2572.
15. Campath (alemtuzumab) [package insert]. Genzyme Corporation, Cambridge, MA 02142. October 2007. Available at:. Accessed November 18, 2011.
16. Syed FF, Bleeker JS, Glockner J, et al. Response to alemtuzumab in FIP1L1/PDGFRA-negative hypereosinophilic myocarditis on serial cardiac magnetic resonance imaging. J Am Coll Cardiol 2012; 59: 430.
17. Butterfield JH, Gleich GJ. Interferon-α treatment of six patients with the idiopathic hypereosinophilic syndrome. Ann Inter Med 1994; 121: 648-653.
18. Butterfield JH, Weiler CR. Use of pegylated interferon in hypereosinophilic syndrome. Leuk Res 2012; 36: 192-197.
19. Pegasys (peginterferon alfa-2a) [package insert]. Genentech USA, South San Francisco, CA, September 2011. Available at:. Accessed November 18, 2011.
20. Plötz S-G, Simon HU, Darsow U, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003; 349: 2334-2339.
21. Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008; 358: 1215-1228.
22. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2005 Oct 25. Identifier NCT00244686, compassionate use of mepolizumab in subjects with hypereosinophilic syndrome (HES); 2011 Nov 10 [cited 2011 Nov 18]. Available at:.
23. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
24. Butterfield JH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Leuk Res 2009; 33: 1127-1129.
25. Klion AD. How I treat hypereosinophilic syndromes. Blood 2009; 114: 3736-3741.